Stock events for Climb Bio, Inc. (CLYM)
Information regarding specific stock events that have impacted Climb Bio, Inc. (CLYM) stock price in the past six months is not available in the provided search results. The company changed its name and ticker symbol from Eliem Therapeutics, Inc. (ELYM) to Climb Bio, Inc. (CLYM) in October 2024.
Demand Seasonality affecting Climb Bio, Inc.’s stock price
Information regarding demand seasonality for Climb Bio, Inc.'s (CLYM) products and services is not available in the provided search results. As a clinical-stage biotechnology company, demand for its products, once commercialized, would likely be driven by disease prevalence and treatment efficacy rather than typical seasonal patterns.
Overview of Climb Bio, Inc.’s business
Climb Bio, Inc. (CLYM) is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, operating within the Healthcare sector, specifically in the Biotechnology industry. Their primary product candidate is budoprutug, an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells and reduce pathogenic autoantibodies, targeting diseases like primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus. Additionally, they are developing CLYM116, a preclinical stage anti-APRIL monoclonal antibody, for the treatment of immunoglobulin A nephropathy (IgAN). The company, formerly known as Eliem Therapeutics, Inc., rebranded to Climb Bio, Inc. in October 2024, with its stock trading under the CLYM ticker since October 3, 2024.
CLYM’s Geographic footprint
Climb Bio, Inc. is headquartered in Wellesley Hills, Massachusetts, United States. The available information does not detail a broader international geographic footprint for its operations or product distribution at this clinical stage.
CLYM Corporate Image Assessment
Information regarding Climb Bio, Inc.'s (CLYM) brand reputation in the past year and any specific events that have affected it is not available in the provided search results. The company's rebranding from Eliem Therapeutics to Climb Bio in October 2024 aimed to reflect its focused mission on immune-mediated diseases.
Ownership
Information regarding major institutional and individual owners of Climb Bio, Inc. (CLYM) is not available in the provided search results.
Ask Our Expert AI Analyst
Price Chart
$1.81
